PowerLine
Posted on August 18, 2024 by Scott Johnson in 2024 Election, Biden Administration, Kamala Harris, Medicare
Big Fakers versus Big Pharma
John A. Clifford is of counsel at Merchant and Gould in Phoenix. He is a member of the Arizona and U.S. Patent Bars. I got to know and respect Jack on the other side of a case premised on the law of intellectual property.
Jack writes to comment on the claim made by Vice President Harris last week that the Biden/Harris administration is “lowering prescription drug costs.” Jack wants it to be noted: “I write as an individual and not on behalf of my employer or any client of that law firm. This is not a legal opinion. I simply asked AI to review the published literature available and tell me when the U.S. patents on these drugs expire. Such information is usually in the annual reports of drug makers and other reliable places. Before making any business decision on this topic, one should review the source documents themselves and not rely on AI or my comment alone.” I thought readers might find his comment (below the break) of interest.
* * * * *
Both President Biden and Vice President Harris spoke at Prince George’s Community College in Largo, Maryland this past Thursday. In their speeches (White House transcript here) they touted the administration’s negotiation of dramatic price reductions on ten pharmaceutical drugs, allegedly saving consumers and Medicare billions of dollars. But as Biden himself noted, the price reductions do not take effect until January 1, 2026. As a patent attorney with some understanding of how things work, I wondered what was going on. Why wait to save billions of dollars?
The agreement covers ten drugs, all of which are covered by one or more U.S. patents. Patents give the owner the legal right to exclude others from making, using or selling an infringing product for a limited time, normally something like 20 years, although with pharmaceuticals the period of exclusivity can be longer for various reasons.
In looking into this claimed Biden/Harris achievement I learned that eight of the ten drugs are covered by patents that expire in 2026 or before. Only one of the ten, Imbruvica, has a patent with many years left to run, and the price reduction negotiated for that drug is the lowest percentage price drop of the group.
Once a drug patent expires generic drug makers are free to enter the market with a generic equivalent, usually at a much lower price. The U.S. government has the details of the drug price reductions contained in the Inflation Reduction Act signed in August of 2022 here: Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026. Included there is this handy chart: